ReFocus: A Phase 1/2 Study of the Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Advanced Solid Tumors Including Breast Cancer

被引：0
|
作者：
Kamath, Suneel
Tai, David
Moreno, Irene
Babiker, Hani
Jin, Zhaohui
Yoo, Changhoon
Ricard, Fabien
Jen, Kai Yu
Coward, Jim
Liu, Jia
Opdam, Frans
Millward, Michael
Ponz-Sarvise, Mariano
Yachnin, Jeffrey
Kim, Richard
Park, Joon Oh
Subbiah, Vivek
Schram, Alison M.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-OT3-24-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT3-24-01
引用
收藏
页数：3
相关论文
共 50 条
  • [41] PHASE 1 STUDY OF THE SELECTIVE AKT INHIBITOR MK-2206 IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
    Tanabe, Y.
    Doi, T.
    Tamura, K.
    Yonemori, K.
    Kodaira, M.
    Fuse, N.
    Bando, H.
    Maeda, Y.
    Shimamoto, T.
    Ohtsu, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 164 - 164
  • [42] Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors
    Dees, E. Claire
    Infante, Jeffrey R.
    Cohen, Roger B.
    O'Neil, Bert H.
    Jones, Suzanne
    von Mehren, Margaret
    Danaee, Hadi
    Lee, Yih
    Ecsedy, Jeffrey
    Manfredi, Mark
    Galvin, Katherine
    Stringer, Bradley
    Liu, Hua
    Eton, Omar
    Fingert, Howard
    Burris, Howard
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (04) : 945 - 954
  • [43] Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors
    E. Claire Dees
    Jeffrey R. Infante
    Roger B. Cohen
    Bert H. O’Neil
    Suzanne Jones
    Margaret von Mehren
    Hadi Danaee
    Yih Lee
    Jeffrey Ecsedy
    Mark Manfredi
    Katherine Galvin
    Bradley Stringer
    Hua Liu
    Omar Eton
    Howard Fingert
    Howard Burris
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 945 - 954
  • [44] Phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations
    Harding, J.
    Perez, C.
    Kato, S.
    Sharma, M.
    Garmezy, B.
    Quah, C.
    Tam, B.
    Severson, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S63 - S64
  • [45] Phase 2 study of futibatinib in patients with specific FGFR aberrations: Activity in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplification
    Satoh, T.
    Barthelemy, P.
    Nogova, L.
    Honda, K.
    Iwasa, S.
    Lee, K.
    Rha, S.
    Ajani, J.
    Hangai, N.
    Liu, S.
    Kremer, J.
    Mina, M.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S165 - S166
  • [46] Phase I study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor, in patients with advanced cholangiocarcinoma, urothelial carcinoma and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations
    Garmezy, B.
    Borad, M.
    Lin, C. C.
    Chen, L. T.
    Perez, C. A.
    Kato, S.
    Tam, B.
    Severson, P.
    Quah, C. S.
    Harding, J. J.
    ANNALS OF ONCOLOGY, 2023, 34 : S231 - S232
  • [47] Phase I study of cediranib, an oral, highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors
    Yamamoto, Noboru
    Yamada, Yasuhide
    Yamada, Kazuhiko
    Nokihara, Hiroshi
    Fujiwara, Yutaka
    Hirata, Taizo
    Yamamoto, Nobuyuki
    Boku, Narikazu
    Shin, Eisei
    Tamura, Tomohide
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3417S - 3418S
  • [48] Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors
    Hong, David S.
    LoRusso, Patricia
    Hamid, Omid
    Janku, Filip
    Kittaneh, Muaiad
    Catenacci, Daniel V. T.
    Chan, Emily
    Bekaii-Saab, Tanios
    Gadgeel, Shirish M.
    Loberg, Robert D.
    Amore, Benny M.
    Hwang, Yuying C.
    Tang, Rui
    Ngarmchamnanrith, Gataree
    Kwak, Eunice L.
    CLINICAL CANCER RESEARCH, 2019, 25 (08) : 2403 - 2413
  • [49] Expansion part of phase I study of E7090 in patients with cholangiocarcinoma harboring FGFR2 gene fusion and with gastric cancer harboring FGFR2 gene amplification or FGFR2 protein high expression
    Morizane, Chigusa
    Ueno, Makoto
    Ioka, Tatsuya
    Tajika, Masahiro
    Ikeda, Masafumi
    Yamaguchi, Kensei
    Hara, Hiroki
    Yabusaki, Hiroshi
    Miyamoto, Atsushi
    Iwasa, Satoru
    Muto, Manabu
    Takashima, Tsutomu
    Minashi, Keiko
    Komatsu, Yoshito
    Nishina, Tomohiro
    Nakajima, Takako Eguchi
    Sahara, Takatoshi
    Funasaka, Setsuo
    Yashiro, Masakazu
    Furuse, Junji
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [50] Preliminary results from a phase 1/2 study of INCB054828, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced malignancies
    Saleh, Mansoor
    Gutierrez, Martin E.
    Subbiah, Vivek
    Smith, David C.
    Asatiani, Ekaterine
    Lihou, Christine F.
    Zhen, Huiling
    Yeleswaram, Swamy
    Ji, Tao
    Nemunaitis, John
    CANCER RESEARCH, 2017, 77
12345